Measuring the Healthy Pediatric Inflammatory Response to Vaccination.

Launched by MAYO CLINIC · Sep 30, 2019

Keywords

ClinConnect Summary

Children who experience seizures that cannot be stopped by traditional anti-seizure medications often suffer profound brain injury and intellectual disability. Indeed, many of these children do not survive. In one study, 12% of children who developed an acute onset disease called FIRES (febrile infection-related epilepsy syndrome) died during the early stages of the disease, and of the children who survived, more than 90% developed cognitive impairment and lifelong epilepsy that could not be treated by our standard drugs. The discovery of new therapeutic strategies is therefore imperative.
...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Children 5-7 months of age receiving the 3rd scheduled dose of the diphtheria, tetanus, pertussis, inactivated polio, Haemophilus influenzae type b, and pneumococcal conjugate vaccine (DTap-IPV/Hib+PCV13).
• • Children 10-18 months of age receiving the 1st scheduled dose of the measles, mumps, rubella, and varicella vaccine (MMR+VZV).
• • Children 4-6 years of age receiving the 2nd scheduled MMR+VZV dose.
• • Children and young adults receiving the annual flu vaccine or COVID vaccine
• Exclusion Criteria:
• • History of autoinflammatory or autoimmune disease.
• • History of genetic or metabolic disorder.
• • History of hematological disorder.
• • History of malignancy or active malignancy undergoing suppressive treatment.
• • Blood donation or collection within 8 weeks of the study.
• • Signs or symptoms consistent with severe infection at the time of first visit.
• • Weight less than 6 kg in group 1, less than 7.5 kg for group 2, less than 12 kg for group 3.